Sector to Reach $34.59 billion by 2028 at a 17.8% CAGR

DUBLIN, Jan. 12, 2023 /PRNewswire/ — The “Asia Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action” Report has been added ResearchAndMarkets.com’s offering.

In the glycomic therapeutics market Asia Pacific It is expected that it will grow from US$ 12,950.82 Million In 2022 US$ 34,592.83 millions It is projected to grow at 17.8% CAGR between 2022-2028.

Glycomics offers new possibilities in precision medicine. This field is currently dominated largely by genetic and proteomic tools. In the next few years, there will be a high demand for glycomics techniques in many therapeutic areas. However, the market for glycomics therapeutics is expected to grow significantly due to ongoing research and development in therapeutics and clinical advances.

Market Overview

Asia Pacific Glycomic therapeutics are booming in Asia Pacific (APAC). The Asia Pacific The market for glycomics therapeutics is segmented. China, Japan, India, South Korea, Australia, and all the rest Asia Pacific. Asia Pacific The growing government support in countries, collaboration with research organizations, rising glycomics institutes, and improving healthcare infrastructure will likely result in a 11.89% market share for glycomic therapeutics in 2022.

The region presents many opportunities for market players in glycomic therapeutics to grow over the forecast period.

Segmentation of Glycomic Therapeutics Markets in Asia Pacific

The Asia Pacific Segmentation of the glycomic therapeutics market can be made on the basis of country, structure, indications, mode-of-action, class and type.

• Based on the class, the Asia Pacific Market for glycomic therapeutics can be divided into synthetic and isolated segments. The market share for synthetics was higher in 2022.

• Structure is the basis of the Asia Pacific glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. In 2022, the market share for glycoproteins was the highest.

• Based on evidence, the Asia Pacific glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022.

• The mode of action determines which type of action is being taken. Asia Pacific glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022.

• The following are the country-specific factors Asia Pacific Segmentation of the glycomic therapeutics market can be found here China, Japan, India, Australia, South Korea, and all the rest Asia Pacific. China The market was dominated in 2022 by GlaxoSmithKline plc. BioMarin Pharmaceutical Inc., Genzyme Corporation Sanofi, Bayer AG, Alzheon, Inc., GlaxoSmithKline plc.F. Hoffmann-La Roche Ltd. is the leader in the glycomic therapy market. Asia Pacific.

We cover the following key topics:

1. Introduction

2. Asia Pacific Glycomic Therapeutics Market: Key Takeaways

3. Research Methodology

4. Asia Pacific Glycomic Therapeutics market – Market Landscape

5. Asia Pacific Glycomic Therapeutics Market: Key Market Dynamics

6. Glycomic Therapy Market Analysis: Asia Pacific

7. Asia Pacific Glycomic Therapeutics Industry Revenue and Forecast to 2028 – by Class

8. Asia Pacific Glycomics Therapeutics Market Forecasts and Analysis to 2028 – By Indication

9. Asia Pacific Glycomic Therapeutics market revenue and forecast to 2028 – by Structures

10. Asia Pacific Glycomic Therapeutics market revenue and forecast to 2028 – by mode of action

11. Asia Pacific Glycomic Therapeutics market revenue and forecasts to 2028 – Country Analysis

12. Glycomic Therapeutics Market Landscape

13. Company Profiles

14. Appendix

Companies Mentioned

Visit this site for more information. https://www.researchandmarkets.com/r/x8a0db

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide the most up-to-date data on global and regional markets as well as key industries and top companies.

Contact Media

Research and Markets
Laura WoodSenior Manager
[email protected]
 
Call +1-917-300-0470 for E.S.T Office Hours
Toll-free call +1 800 526-8630 for U.S. and CAN
For GMT Office Hours: Call +353-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View the original contenthttps://www.prnewswire.com/news-releases/asia-pacific-glycomic-therapeutics-market-report-2023-sector-to-reach-34-59-billion-by-2028-at-a-cagr-of-17-8-301719944.html

SOURCE Research and Markets